glp-1 aspiration GLP-1s May Lead to an Increased Risk of Post-Endoscopy Pneumonia GLP-1 Agonists For Obesity In

Medicare does already cover GLP-1 for some non-weight-loss indications: Part D covers Ozempic and Mounjaro for type 2 diabetes, and Wegovy received a new indication for cardiovascular risk reduction in patients with established heart disease and obesity

It works by replicating the bodys natural hormone GLP-1, which is responsible for regulating appetite, digestion, and blood sugar balance

But did you know that recent evidence shows these new drugs may do more than just help with weight loss and diabetes

Shorter courses produce less total weight loss and may not allow enough time for metabolic adaptation

Compared with GLP-1, dual agonists can avoid the degradation of dipeptidyl peptidase-4, thereby prolongating drug administration

Weight loss can cause bone loss for anyone